中文字幕亚洲欧美日韩在线不卡,夜夜爽夜夜叫夜夜高潮漏水,怡红院a∨人人爰人人爽,夜夜高潮夜夜爽夜夜爱爱

網站公告
廣州楊葉生物 專業供應進口:、、克霉唑、、達克羅寧原料藥 質量保證 價格優惠!
產品分類
聯系方式
您當前的位置:首頁 » 供應產品 » 蘋果酸鹽原料藥小分子抑制劑 研究用藥效強 現貨供應
蘋果酸鹽原料藥小分子抑制劑 研究用藥效強 現貨供應
點擊圖片查看大圖
產品/服務: 瀏覽次數:188蘋果酸鹽原料藥 
型 號: 942275-12-9 
規 格: 醫藥級 
品 牌: yanyebio 
單 價: 1.00元/公斤 
起訂量: 1 公斤 
供貨總量: 1135 公斤
發貨期限: 自買家付款之日起 3 天內發貨
更新日期: 2017-04-07  有效期至:長期有效
聯 系 人: ( 登錄可見 )
公司電話: ( 登錄可見 )
即時通訊: ( 登錄可見 )


«上一個產品     下一個產品»
產品屬性
 產品型號:  942275-12-9
 產品規格:  醫藥級
 產品品牌:  yanyebio
產品優勢
蘋果酸鹽原料藥 小分子抑制劑 研究用藥效強 現貨供應順豐發貨僅供科研
詳細信息

蘋果酸鹽原料藥 小分子抑制劑 研究用藥效強 現貨供應順豐發貨僅供科研
產品名稱:蘋果酸鹽
產品別名:Cabozantinib malate (XL184)
CAS.NO:1140909-48-3
分子式:C28H24FN3O5.C4H6O5
分子量:635.59
純度級別:實驗試劑LR
產品性狀:固態粉末
穩定性:3年 -20℃粉狀 6個月-80℃溶于溶劑
有效成分含量:99%
用途:科研
產品描述:Cabozantinib malate (XL184)是Cabozantinib的蘋果酸鹽,是有效的VEGFR2抑制劑,IC50為0.035 nM,也抑制c-Met, Ret, Kit, Flt-1/3/4, Tie2和AXL,無細胞試驗中IC50分別為1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM和7 nM。
靶點:VEGFR2/KDR [1] c-Met [1] Kit [1] VEGFR3/FLT4 [1] Axl [1]
體外研究:Cabozantinib has weak inhibitory activity against RON and PDGFRβ with IC50 of 124 nM and 234 nM, respectivey, and has low activity against FGFR1 with IC50 of 5.294 μM. [1] Cabozantinib at low concentration (0.1-0.5 μM) is sufficient to induce marked inhibition of constitutive and inducible Met phosphorylation and its resultant downstream signaling in MPNST cells, and inhibit HGF-induced MPNST cell migration and invasion. Cabozantinib also induces marked inhibition of Met and VEGFR2 phosphorylation in cytokine-stimulated human umbilical vein endothelial cells (HUVECs). Although Cabozantinib has no significant effect on MPNST cell growth at 0.1 μM, Cabozantinib at 5-10 μM significantly inhibits the MPNST cell growth. [2]
體內研究:Cabozantinib treatment at 30 mg/kg in RIP-Tag2 mice with spontaneous pancreatic islet tumors disrupts 83% of the tumor vasculature, reduces pericytes and empty basement membrane sleeves, causes widespread intratumoral hypoxia and extensive tumor cell apoptosis, and slows regrowth of the tumor vasculature after drug withdrawal, more significantly compared with XL999 that blocks VEGFR but not c-Met, leading to only 43% reduction in vascularity, suggesting that concurrent inhibition of VEGFR and other functionally relevant receptor tyrosine kinases (RTK) amplifies angiogenesis inhibition. Cabozantinib also decreases invasiveness of primary tumors and reduces metastasis. [1] Cabozantinib at 30 mg/kg/day significantly abrogates human MPNST xenografts growth and metastasis in SCID mice. [2] Administration of Cabozantinib induces dose-dependent inhibition of tumor growth in breast, lung, and glioma tumor models, in association with decreased tumor and endothelial cell proliferation as well as increased apoptosis. A single oral dose of Cabozantinib is sufficient to induce sustained tumor growth inhibition in MDA-MB-231 tumor-bearing mice and C6 tumor-bearing rats at 100 mg/kg and 10 mg/kg, respectively. [3]









相關產品
0條  相關評論
 免責聲明:(1)以上所展示的信息由企業自行提供,內容的真實性、準確性和合法性由發布企業負責,環球塑化網對此不承擔任何保證責任。我們原則上建議您優先選擇“塑企通”會員合作! (2)同時我們鄭重提醒各位買/賣家,交易前請詳細核實對方身份,切勿隨意打款或發貨,謹防上當受騙。如發現虛假信息,請向環球塑化網舉報。
網站首頁公司介紹供應產品新聞中心榮譽資質人才招聘聯系方式舉報
©2025 環球塑化網 版權所有   技術支持: 環球塑化網     訪問量:11621  管理入口

收縮
  • 電話咨詢

  • 020-85647089
QR code
關閉
關閉
請輸入驗證碼